"Original antigenic sin": A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants.
作者信息
Noori Maryam, Nejadghaderi Seyed Aria, Rezaei Nima
机构信息
Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
出版信息
Infect Control Hosp Epidemiol. 2022 Aug;43(8):1091-1092. doi: 10.1017/ice.2021.199. Epub 2021 May 3.
Abstract
摘要
相似文献
1
"Original antigenic sin": A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants.“原始抗原罪”：针对新型SARS-CoV-2变体加强疫苗接种之外的潜在威胁。
Infect Control Hosp Epidemiol. 2022 Aug;43(8):1091-1092. doi: 10.1017/ice.2021.199. Epub 2021 May 3.
2
SARS-CoV-2 vaccination washes away original antigenic sin.新型冠状病毒2型疫苗接种消除了原始抗原罪。
Trends Immunol. 2022 Apr;43(4):271-273. doi: 10.1016/j.it.2022.02.009. Epub 2022 Feb 28.
3
SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis.接受透析患者的新型冠状病毒2型加强疫苗反应
Clin J Am Soc Nephrol. 2022 Jul;17(7):1036-1038. doi: 10.2215/CJN.00890122. Epub 2022 Apr 5.
4
Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization.评价 SARS-CoV-2 变异株在初次免疫和加强免疫后，基于假病毒中和试验的免疫原性。
Int J Infect Dis. 2022 Apr;117:97-102. doi: 10.1016/j.ijid.2022.01.068. Epub 2022 Feb 2.
5
SARS-CoV-2 vaccination in the context of original antigenic sin.SARS-CoV-2 疫苗接种与原始抗原性错误。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1949953. doi: 10.1080/21645515.2021.1949953. Epub 2021 Jul 9.
6
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.加强针对 SARS-CoV-2 奥密克戎变异株的 COVID-19 疫苗接种：系统评价。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2062983. doi: 10.1080/21645515.2022.2062983. Epub 2022 May 2.
7
Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice.体液免疫应答对用不同受体结合域亚单位增强接种后循环中的真实严重急性呼吸综合征冠状病毒 2 变体的小鼠
J Med Virol. 2022 Sep;94(9):4533-4538. doi: 10.1002/jmv.27882. Epub 2022 Jun 3.
8
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.癌症患者在接种完初始系列疫苗和加强针 SARS-CoV-2 疫苗后对 SARS-CoV-2 病毒变异株的中和广度。
Cancer Cell. 2022 Jan 10;40(1):103-108.e2. doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 5.
9
Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination.抗原图谱表明，在接种卫星五号疫苗后进行同源（卫星五号）或异源（Comirnaty）加强针后，奥密克戎 BA.1 和 BA.4/BA.5 变体与原始 SARS-CoV-2 仍然具有抗原差异。
Int J Mol Sci. 2023 Jun 22;24(13):10493. doi: 10.3390/ijms241310493.
10
Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen.接种奥密克戎刺突受体结合域疫苗可提高广泛中和抗体水平，即使在获得对原始抗原的免疫力后也能提供持续保护。
Int Immunol. 2023 Apr 4;35(4):197-207. doi: 10.1093/intimm/dxac055.
引用本文的文献
1
The "original antigenic sin" and its relevance for SARS-CoV-2 (COVID-19) vaccination.“原始抗原罪”及其与严重急性呼吸综合征冠状病毒2（SARS-CoV-2，即新型冠状病毒肺炎）疫苗接种的相关性。
Clin Immunol Commun. 2021 Dec;1:13-16. doi: 10.1016/j.clicom.2021.10.001. Epub 2021 Oct 8.
2
Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin.接种疫苗会损害针对奥密克戎突破性感染的新免疫反应，这是原始抗原性错误的前提条件。
Nat Commun. 2024 Apr 10;15(1):3102. doi: 10.1038/s41467-024-47451-w.
3
Investigating the Antibody Imprinting Hypothesis among Canadian Paramedics after SARS-CoV-2 Omicron Variant Circulation.调查 SARS-CoV-2 奥密克戎变异株流行后加拿大护理人员中的抗体印迹假说。
Immunohorizons. 2024 Feb 1;8(2):193-197. doi: 10.4049/immunohorizons.2400010.
4
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine.评估非佐剂AKS-452 SARS-CoV-2 RBD Fc疫苗加强免疫能力的免疫原性II期研究。
NPJ Vaccines. 2024 Feb 21;9(1):40. doi: 10.1038/s41541-024-00830-2.
5
COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.新冠病毒mRNA疫苗：注册试验和全球疫苗接种运动的经验教训
Cureus. 2024 Jan 24;16(1):e52876. doi: 10.7759/cureus.52876. eCollection 2024 Jan.
6
Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain.基于SARS-CoV-2毒株的疫苗序贯接种可有效诱导针对此前未接触过的奥密克戎毒株的强效免疫反应。
Pathogens. 2023 Apr 28;12(5):655. doi: 10.3390/pathogens12050655.
7
Vaccines against Group B Coxsackieviruses and Their Importance.抗B组柯萨奇病毒疫苗及其重要性。
Vaccines (Basel). 2023 Jan 27;11(2):274. doi: 10.3390/vaccines11020274.
8
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.一项蒙塔尼德佐剂的 SARS-CoV-2 刺突蛋白-RBD-Fc 疫苗，AKS-452 的随机 I/II 期安全性和免疫原性研究。
Vaccine. 2023 Mar 24;41(13):2184-2197. doi: 10.1016/j.vaccine.2023.02.057. Epub 2023 Feb 23.
9
Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review.SARS-CoV-2 突破性感染全景：综述。
Medicina (Kaunas). 2022 Nov 27;58(12):1733. doi: 10.3390/medicina58121733.
10
"Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection.感染后接种新冠病毒疫苗中的“原始抗原原罪”
Cureus. 2022 Dec 15;14(12):e32548. doi: 10.7759/cureus.32548. eCollection 2022 Dec.
本文引用的文献
1
Immunological imprinting of the antibody response in COVID-19 patients.COVID-19 患者的抗体反应的免疫印迹。
Nat Commun. 2021 Jun 18;12(1):3781. doi: 10.1038/s41467-021-23977-1.
2
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.新冠病毒变异株B.1.429和B.1.351的中和作用
N Engl J Med. 2021 Jun 17;384(24):2352-2354. doi: 10.1056/NEJMc2103740. Epub 2021 Apr 7.
3
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.循环中的新冠病毒变异株的中和敏感性。
N Engl J Med. 2021 Jun 17;384(24):2354-2356. doi: 10.1056/NEJMc2103022. Epub 2021 Apr 6.
4
New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.新型严重急性呼吸综合征冠状病毒2变体——对临床、公共卫生及疫苗的影响
N Engl J Med. 2021 May 13;384(19):1866-1868. doi: 10.1056/NEJMc2100362. Epub 2021 Mar 24.
5
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
6
Neutralizing Activity of BNT162b2-Elicited Serum.BNT162b2诱导血清的中和活性
N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.
7
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.对 COVID-19 患者的病毒表位分析揭示了交叉反应性和严重程度的相关性。
Science. 2020 Nov 27;370(6520). doi: 10.1126/science.abd4250. Epub 2020 Sep 29.
8
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.新冠病毒和非典病毒感染之间的交叉反应性抗体反应。
Cell Rep. 2020 Jun 2;31(9):107725. doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
9
Original antigenic sin: A comprehensive review.原始抗原性失误：全面回顾。
J Autoimmun. 2017 Sep;83:12-21. doi: 10.1016/j.jaut.2017.04.008. Epub 2017 May 5.
10
Updated, augmented vaccines compete with original antigenic sin.更新、增强的疫苗与原始抗原原罪相互竞争。
Nat Med. 2015 Jun;21(6):540-1. doi: 10.1038/nm0615-540.
Zotero 插件